Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2016

01-10-2016 | Original Article

MicroRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer

Authors: Guiqi Wang, Jingfeng Gu, Yingchao Gao

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

Cysteine-rich protein 61 (CYR61) and metastasis associated in colon cancer (MACC1) protein promoted human colorectal cancer (CRC) cell metastasis and closely related to the patient’s prognosis in colorectal cancer. The purpose of this article is to investigate whether CYR61 and MACC1 can serve as dual potential targets for gene therapy of human CRC. In this study, microRNA (miRNA) targeting for both CYR61 and MACC1 was used to investigate the mechanism and therapeutic effects for CRC cells and mice with CRC. We observed that silencing miRNA for CYR61 and MACC1 inhibited the epithelial-mesenchymal transition (EMT) process, and co-treatment strengthened this effect. MTT assay showed that the growth of colorectal tumor cells was decreased due to miRNA treatment. Apoptosis assay revealed that miRNA for CYR61 and MACC1 promoted CRC cells apoptotic. The animals’ study results showed that the expression levels of CYR61 and MACC1 were significantly decreased after miRNA-100 and miRNA-143 treatment, respectively. The expression levels of apoptosis-promoting protein were increased significantly after treatment with miRNA-100 and miRNA-143, which suggested that both miRNA-100 and miRNA-143 may induce apoptosis by mitochondria-dependent pathway. In addition, metastasis and invasion assays showed that miRNA-100 and miRNA-143 treatment inhibited obviously migratory and invasive abilities of CRC cells. Furthermore, our data also showed that the tumor growth was significantly inhibited and survival rate of tumor-bearing mice was greatly improved by common treatments of miRNA-100 and miRNA-143. In conclusion, the abilities of apoptosis, metastasis, and invasion in CRC tumor cells were significantly suppressed by miRNA-100 and miRNA-143 targeting CYR61 and MACC1, respectively. As a result, CYR61 and MACC1 may serve as potential targets for gene therapy in human CRC treatments.
Literature
1.
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64:104–17.
2.
Chibaudel B, Bonnetain F, Tournigand C, de Gramont A. Maintenance treatment in metastatic colorectal cancer. The lancet oncology. 2015;16:e583–584.CrossRefPubMed
3.
Moilanen JM, Kokkonen N, Loffek S, Vayrynen JP, Syvaniemi E, Hurskainen T, et al. Collagen XVII expression correlates with the invasion and metastasis of colorectal cancer. Human pathology. 2015;46:434–42.CrossRefPubMed
4.
Fan Z, Cui H, Xu X, Lin Z, Zhang X, Kang L, et al. Mir-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting stat3. Oncotarget. 2015;6:25266–80.CrossRefPubMedPubMedCentral
5.
Zhang XB, Song L, Wen HJ, Bai XX, Li ZJ, Ma LJ. Upregulation of microRNA-31 targeting integrin alpha5 suppresses tumor cell invasion and metastasis by indirectly regulating pi3k/akt pathway in human gastric cancer sgc7901 cells. Tumour Biol. 2016;37(6):8317–25.CrossRefPubMed
6.
Guo J, Yu X, Gu J, Lin Z, Zhao G, Xu F, et al. Regulation of cxcr4/akt-signaling-induced cell invasion and tumor metastasis by RhoA, Rac-1, and Cdc42 in human esophageal cancer. Tumour Biol 2016;37(5):6371–8.
7.
Jiang N, Deng JY, Liu Y, Ke B, Liu HG, Liang H. Incorporation of perineural invasion of gastric carcinoma into the 7th edition tumor-node-metastasis staging system. Tumour Biol. 2014;35:9429–36.CrossRefPubMed
8.
Bukurova Iu A, Khankin SL, Krasnov GS, Grigor’eva ES, Mashkova TD, Lisitsin NA, et al. Comparison of 2D analysis and bioinformatics search efficiency for colon cancer marker identification. Molekuliarnaia biologiia. 2010;44:375–81.PubMed
9.
Thompson BA, Goldgar DE, Paterson C, Clendenning M, Walters R, Arnold S, et al. A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the colon cancer family registry. Human mutation. 2013;34:200–9.CrossRefPubMed
10.
He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nature reviews Genetics. 2004;5:522–31.CrossRefPubMed
11.
Chen Y, Wakili R, Xiao J, Wu CT, Luo X, Clauss S, et al. Detailed characterization of microRNA changes in a canine heart failure model: relationship to arrhythmogenic structural remodeling. Journal of molecular and cellular cardiology. 2014;77:113–24.CrossRefPubMed
12.
Santos-Carballal B, Aaldering LJ, Ritzefeld M, Pereira S, Sewald N, Moerschbacher BM, et al. Physicochemical and biological characterization of chitosan-microRNA nanocomplexes for gene delivery to mcf-7 breast cancer cells. Scientific reports. 2015;5:13567.CrossRefPubMedPubMedCentral
13.
Ozek NS, Tuna S, Erson-Bensan AE, Severcan F. Characterization of microRNA-125b expression in MCF7 breast cancer cells by ATR-FTIR spectroscopy. The Analyst. 2010;135:3094–102.CrossRefPubMed
14.
Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. American Journal of Respiratory Cell and Molecular Biology. 2010;42:312–9.CrossRefPubMed
15.
Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, et al. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer. 2013;119:814–24.CrossRefPubMed
16.
Konishi H, Fujiya M, Ueno N, Moriichi K, Sasajima J, Ikuta K, et al. MicroRNA-26a and -584 inhibit the colorectal cancer progression through inhibition of the binding of HNRNP A1-CDK6 mRNA. Biochemical and biophysical research communications. 2015;467:847–52.CrossRefPubMed
17.
Fei BY, Wang XY, Fang XD. MicroRNA-143 replenishment re-sensitizes colorectal cancer cells harboring mutant, but not wild-type, kras to paclitaxel treatment. Tumour Biol. 2016;37(5):5829–35.
18.
Xu ST, Ding X, Ni QF, Jin SJ. Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in t24 cells. International journal of clinical and experimental pathology. 2015;8:7937–44.PubMedPubMedCentral
19.
Han S, Bui NT, Ho MT, Kim YM, Cho M, Shin DB. Dexamethasone inhibits tgf-beta1-induced cell migration by regulating the erk and akt pathways in human colon cancer cells via CYR61. Cancer Res Treat. 2016;48(3):1141–53.
20.
Haque I, Banerjee S, Mehta S, De A, Majumder M, Mayo MS, et al. Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (ccn5)/WNT-1-induced signaling protein-2 (wisp-2) regulates microRNA-10b via hypoxia-inducible factor-1alpha-twist signaling networks in human breast cancer cells. The Journal of biological chemistry. 2011;286:43475–85.CrossRefPubMedPubMedCentral
21.
Osaki M, Inaba A, Nishikawa K, Sugimoto Y, Shomori K, Inoue T, et al. Cysteine-rich protein 61 suppresses cell invasion via down-regulation of matrix metalloproteinase-7 expression in the human gastric carcinoma cell line mkn-45. Molecular medicine reports. 2010;3:711–5.CrossRefPubMed
22.
Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ, Xie D. Involvement of CYR61 in growth, migration, and metastasis of prostate cancer cells. British journal of cancer. 2008;99:1656–67.CrossRefPubMedPubMedCentral
23.
Sun L, Duan J, Jiang Y, Wang L, Huang N, Lin L, et al. Metastasis-associated in colon cancer-1 upregulates vascular endothelial growth factor-c/d to promote lymphangiogenesis in human gastric cancer. Cancer letters. 2015;357:242–53.CrossRefPubMed
24.
Lederer A, Herrmann P, Seehofer D, Dietel M, Pratschke J, Schlag P, et al. Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients. Hepatology. 2015;62:841–50.CrossRefPubMed
25.
Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. Macc1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nature medicine. 2009;15:59–67.CrossRefPubMed
26.
Boardman LA. Overexpression of MACC1 leads to downstream activation of hgf/met and potentiates metastasis and recurrence of colorectal cancer. Genome medicine. 2009;1:36.CrossRefPubMedPubMedCentral
27.
Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Hanagiri T, Oyama T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. The Journal of thoracic and cardiovascular surgery. 2011;141:895–8.CrossRefPubMed
28.
Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, et al. Mir-1 downregulation cooperates with MACC1 in promoting met overexpression in human colon cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18:737–47.CrossRef
29.
Yang T, Kong B, Kuang YQ, Cheng L, Gu JW, Zhang JH, et al. Overexpression of MACC1 protein and its clinical implications in patients with glioma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35:815–9.CrossRef
30.
Wang Z, Li Z, Wu C, Wang Y, Xia Y, Chen L, et al. Macc1 overexpression predicts a poor prognosis for non-small cell lung cancer. Med Oncol. 2014;31:790.CrossRefPubMed
31.
Wang G, Fu Z, Li D. Macc1 overexpression and survival in solid tumors: a meta-analysis. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015;36:1055–65.CrossRef
32.
Li H, Zhang H, Zhao S, Shi Y, Yao J, Zhang Y, et al. Overexpression of MACC1 and the association with hepatocyte growth factor/c-met in epithelial ovarian cancer. Oncology letters. 2015;9:1989–96.PubMedPubMedCentral
33.
Da Ros VG, Gutierrez-Perez I, Ferres-Marco D, Dominguez M. Dampening the signals transduced through hedgehog via microRNA MIR-7 facilitates notch-induced tumourigenesis. PLoS biology. 2013;11:e1001554.CrossRefPubMedPubMedCentral
34.
Wai-Hoe L, Wing-Seng L, Ismail Z, Lay-Harn G. Sds-page-based quantitative assay for screening of kidney stone disease. Biological procedures online. 2009;11:145–60.CrossRefPubMedPubMedCentral
35.
Bai FL, Yu YH, Tian H, Ren GP, Wang H, Zhou B, et al. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biology & Therapy. 2014;15:1226–38.CrossRef
36.
Yang L, Wu X, Liu F, Duan Y, Li S. Novel biodegradable polylactide/poly(ethylene glycol) micelles prepared by direct dissolution method for controlled delivery of anticancer drugs. Pharmaceutical research. 2009;26:2332–42.CrossRefPubMed
37.
Zhang Y, Wang Z, Chen M, Peng L, Wang X, Ma Q, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Molecular cancer. 2012;11:23.CrossRefPubMedPubMedCentral
38.
Zhang Y, Diao Z, Su L, Sun H, Li R, Cui H, et al. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. Am J Obstet Gynecol. 2010;202:466. e461-467.CrossRefPubMed
39.
Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. British journal of cancer. 2015;113:569–73.CrossRefPubMedPubMedCentral
40.
Pooja T, Karunagaran D. Emodin suppresses WNT signaling in human colorectal cancer cells sw480 and sw620. European Journal of Pharmacology. 2014;742:55–64.CrossRefPubMed
41.
Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad O. Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer. 2004;40:1593–8.CrossRefPubMed
42.
Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nature reviews Clinical oncology. 2011;8:467–77.CrossRefPubMedPubMedCentral
43.
Isella C, Mellano A, Galimi F, Petti C, Capussotti L, De Simone M, et al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Annals of surgery. 2013;257:1089–95.CrossRefPubMed
44.
Nicolas FJ, Lehmann K, Warne PH, Hill CS, Downward J. Epithelial to mesenchymal transition in Madin-Darby canine kidney cells is accompanied by down-regulation of SMAD3 expression, leading to resistance to transforming growth factor-beta-induced growth arrest. The Journal of biological chemistry. 2003;278:3251–6.CrossRefPubMed
45.
Lemos C, Hardt MS, Juneja M, Voss C, Forster S, Jerchow B, et al. Macc1 induces tumor progression in transgenic mice and colorectal cancer patients via increased pluripotency markers nanog and oct4. Clin Cancer Res. 2016;22(11):2812–24.
46.
47.
Ren B, Zakharov V, Yang Q, McMahon L, Yu J, Cao W. Macc1 is related to colorectal cancer initiation and early-stage invasive growth. American journal of clinical pathology. 2013;140:701–7.CrossRefPubMed
48.
Ladwa R, Pringle H, Kumar R, West K. Expression of CTGF and CYR61 in colorectal cancer. Journal of clinical pathology. 2011;64:58–64.CrossRefPubMed
49.
Ilm K, Kemmner W, Osterland M, Burock S, Koch G, Herrmann P, et al. High MACC1 expression in combination with mutated kras g13 indicates poor survival of colorectal cancer patients. Molecular cancer. 2015;14:38.CrossRefPubMedPubMedCentral
50.
Jeong D, Heo S, Sung Ahn T, Lee S, Park S, Kim H, et al. Cyr61 expression is associated with prognosis in patients with colorectal cancer. BMC cancer. 2014;14:164.CrossRefPubMedPubMedCentral
51.
Zaharie F, Muresan MS, Petrushev B, Berce C, Gafencu GA, Selicean S, et al. Exosome-carried microRNA-375 inhibits cell progression and dissemination via bcl-2 blocking in colon cancer. Journal of gastrointestinal and liver diseases: JGLD. 2015;24:435–43.PubMed
52.
Riethmuller M, Burger N, Bauer G. Singlet oxygen treatment of tumor cells triggers extracellular singlet oxygen generation, catalase inactivation and reactivation of intercellular apoptosis-inducing signaling. Redox biology. 2015;6:157–68.CrossRefPubMedPubMedCentral
53.
Sampath D, Winneker RC, Zhang Z. Cyr61, a member of the ccn family, is required for mcf-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer. Endocrinology. 2001;142:2540–8.PubMed
54.
Huang Y, Zhang H, Cai J, Fang L, Wu J, Ye C, et al. Overexpression of MACC1 and its significance in human breast cancer progression. Cell & Bioscience. 2013;3:16.CrossRef
55.
Lin L, Huang H, Liao W, Ma H, Liu J, Wang L, et al. Macc1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect. Oncogene. 2015;34:2700–10.CrossRefPubMed
56.
Simmer F, Venderbosch S, Dijkstra JR, Vink-Borger EM, Faber C, Mekenkamp LJ, et al. MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Oncotarget. 2015;6:22996–3007.CrossRefPubMedPubMedCentral
57.
Zhang S, Yuan W, Tang W, Xu C, Ma J. Expression of microRNA-100 and its relation with prognosis of colorectal cancer. Zhonghua zhong liu za zhi Chinese J Oncol 2015;37:603-608.
Metadata
Title
MicroRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer
Authors
Guiqi Wang
Jingfeng Gu
Yingchao Gao
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5252-2

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue

Review

Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors

Original Article

Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma

Original Article

A guide for the analysis of long-term population growth in cancer

Original Article

Long noncoding RNA BCAR4 promotes osteosarcoma progression through activating GLI2-dependent gene transcription

Original Article

Mucin-1 correlates with survival, smoking status, and growth patterns in lung adenocarcinoma

Original Article

Identification of a five-lncRNA signature for the diagnosis and prognosis of gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits